| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/30-1/150 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/5000-1/10000 | Human,Mouse,Rat |
| Aliases | 19A; CS1; CD319; CRACC |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein of human SLAMF7 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是关于SLAMF7抗体的3篇代表性文献及简要摘要：
1. **"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma"**
- **作者**: Lonial S 等
- **摘要**: 该研究报道了靶向SLAMF7的单抗药物Elotuzumab在复发/难治性多发性骨髓瘤(MM)患者中的III期临床试验结果。结果显示，Elotuzumab联合来那度胺和地塞米松显著延长无进展生存期，证实其通过激活NK细胞介导的抗体依赖性细胞毒性(ADCC)发挥抗肿瘤作用。
2. **"CS1 (SLAMF7) is a Novel Therapeutic Target in Multiple Myeloma"**
- **作者**: Hsi ED 等
- **摘要**: 文章阐明了SLAMF7(又称CS1)在多发性骨髓瘤细胞中的高表达及其作为治疗靶点的潜力。通过临床前实验证明，靶向SLAMF7的抗体可通过直接抑制肿瘤细胞增殖并增强免疫细胞杀伤功能发挥疗效。
3. **"SLAMF7 in Hematological Malignancies: From Diagnosis to Therapy"**
- **作者**: van Rhee F 等
- **摘要**: 综述总结了SLAMF7在血液肿瘤(如多发性骨髓瘤)中的生物学功能，重点讨论了Elotuzumab的临床开发进展及其联合用药策略，强调其通过双重机制(靶向肿瘤细胞+调节免疫微环境)实现治疗效果。
4. **"Elotuzumab enhances natural killer cell activation and myeloma cell killing through interleukin-2 and IFN-γ pathways"**
- **作者**: Balasa B 等
- **摘要**: 该研究揭示了Elotuzumab激活NK细胞的具体机制，包括促进IL-2分泌和IFN-γ通路活化，从而增强对SLAMF7阳性骨髓瘤细胞的清除，为联合免疫疗法提供了理论依据。
以上文献涵盖临床研究、靶点机制及联合治疗策略，反映了SLAMF7抗体在肿瘤免疫治疗中的核心进展。
The SLAMF7 (Signaling Lymphocyte Activation Molecule Family member 7) antibody is a therapeutic agent targeting the SLAMF7 receptor, a cell surface glycoprotein primarily expressed on immune cells, including natural killer (NK) cells, plasma cells, and certain T-cell subsets. SLAMF7. also known as CD319 or CS1. plays a critical role in regulating immune cell activation and adhesion. It mediates pro-survival signals in malignant plasma cells, making it a key target in multiple myeloma (MM) treatment.
Elotuzumab, the first FDA-approved SLAMF7 monoclonal antibody, exemplifies its clinical application. By binding to SLAMF7. elotuzumab exhibits dual mechanisms: directly targeting MM cells via SLAMF7 overexpression while enhancing NK cell-mediated antibody-dependent cellular cytotoxicity (ADCC). Unlike traditional monoclonal antibodies, it does not induce complement-dependent cytotoxicity (CDC) or direct apoptosis. Instead, it relies on immune modulation by activating NK cells through interactions with Fcγ receptors.
Clinical trials, such as the ELOQUENT-2 study, demonstrated improved progression-free survival when elotuzumab was combined with lenalidomide and dexamethasone in relapsed/refractory MM. Research also explores SLAMF7's broader role in autoimmune diseases and viral infections due to its involvement in lymphocyte signaling. Despite its success, resistance mechanisms and optimal combination strategies remain active areas of investigation. SLAMF7-targeted therapies highlight the growing importance of immunomodulatory antibodies in oncology.
×
